# Peptides and oligonucleotides: Production

Why a few Swiss plants and two drug giants dominate

Source page: https://www.materialinsights.org/chemicals/peptides_oligos/production/

What this tab covers Who makes it and how much: world capacity and output, utilisation, the top producing countries and companies globally and in India, concentration, new capacity coming, and each region's position.

| Measure | Figure | Detail | Source |
|---|---|---|---|
| **World capacity** | not published |  |  |
| **World output** | not published |  |  |
| **Capacity utilisation** | tight in 2023-2026 for GLP-1 APIs | CDMOs signed multi-year contracts (CordenPharma about EUR 3 billion) and are building capacity. FDA ended the semaglutide shortage listing in 2025 (indicative). | IntuitionLabs citing CordenPharma (2026) |
| **Concentration** | originators (Novo, Lilly) make most GLP-1 API in house; outsourced peptide market led by Bachem, CordenPharma, PolyPeptide (indicative) | Shares not published. | qualitative |
| **New capacity** | Bachem capex above CHF 400 million in 2026; CordenPharma EUR 900 million (2024-2027) | Bachem Building K first phase approved by Swiss regulator end-2025, ramping in 2026; Bachem bought plots at Sisslerfeld (Eiken). Samsung-PolyPeptide deal closing end-2026. Lonza considering a $1 billion Ohio plant. | Bachem FY2025; IntuitionLabs (2026); GEN (2026) |

#### Top producing countries

- **Switzerland**: Bachem (Bubendorf, Vionnaz), PolyPeptide, Lonza
- **Denmark and US**: Novo Nordisk and Eli Lilly captive GLP-1 API
- **China**: WuXi TIDES, Hybio and many generic peptide makers
- **India**: emerging: generic semaglutide makers and CDMO peptide capacity (Laurus, Divi's)
- **Korea and Japan**: ST Pharm (oligos), Samsung Biologics (via PolyPeptide bid), Nitto Avecia
 Bachem FY2025; qualitative; Laurus FY26; BoB on Divi's (2026); GEN (2026); qualitative

#### Largest producers: global

| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| **Bachem** EBITDA margin 30.9%; capex over CHF 400 million in 2026 | Switzerland | 695 CHF million sales | 2025 | [Bachem FY2025 media release](https://www.bachem.com/wp-content/uploads/2026/03/Media-Release-Financial-Year-2025_final.pdf) |
| **CordenPharma** EUR 900 million peptide investment announced July 2024 | Germany / Switzerland | not published | 2024 | [IntuitionLabs](https://intuitionlabs.ai/articles/top-cdmo-companies-2026-ranked) |
| **PolyPeptide Group** deal expected to close end-2026 | Switzerland | 1.46 CHF billion equity value in Samsung offer | 2026 | [GEN Top 10 CDMOs 2026](https://www.genengnews.com/topics/bioprocessing/top-10-contract-development-and-manufacturing-organizations-2026/) |
| **WuXi AppTec (WuXi TIDES)** 1260H listing June 2026 | China | not published | 2026 | [FDA Law Blog](https://www.thefdalawblog.com/2026/06/wuxi-apptecs-1260h-listing-brings-the-biosecure-act-back-to-center-stage/) |
| **Novo Nordisk** captive API | Denmark | 13.8 $ billion Ozempic sales | 2023 | [DCAT](https://www.dcatvci.org/features/the-cdmo-cmo-suppliers-report-the-rising-strength-of-tides) |

#### Largest producers: India

| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| **Divi's Laboratories** solid and liquid peptide investment | India | not published | FY26 | [BoB Capital](https://www.barodaetrade.com/Reports/DivisLabs-Q4FY26ResultReview24May26-Research.pdf) |
| **Laurus Labs** peptide capex FY27-28 | India | not published | FY26 | [Laurus FY26 press release](https://www.lauruslabs.com/Investors/PDF/PressReleases/PressRelease-Laurus-Labs-Announces-Full-Year-FY26-Results-Revenues-at-₹6_813Cr_EBITDAat₹1_826Cr_ 26.8_ margins.pdf) |
| **Dr Reddy's, Sun, Zydus, Biocon** launches after Indian semaglutide patent expiry, March 2026 (indicative) | India | not published | 2026 | press reports (indicative) |

India has no large peptide API plant yet comparable to Bachem's; capacity is being built by Divi's, Laurus and generic makers. Oligonucleotide API manufacturing in India is minimal (not confirmed).

#### Position by region

| Region | Position |
|---|---|
| **US** | BIOSECURE Act may shift peptide and oligo outsourcing away from WuXi; Lilly and Novo building US API plants. |
| **EU** | Home of Bachem, PolyPeptide, CordenPharma; REACH limits on DMF and NMP. |
| **India** | Generic GLP-1 market opened in 2026; CDMOs building peptide plants. |
| **China** | Strong generic peptide base; WuXi TIDES under US pressure. |
| **Japan** | Nitto Avecia, Ajinomoto in oligos. |
| **Middle East** | Not material. |

## Other sections

- [Summary](https://www.materialinsights.org/chemicals/peptides_oligos/index.md)
- [Overview](https://www.materialinsights.org/chemicals/peptides_oligos/overview/index.md)
- [Correlation](https://www.materialinsights.org/chemicals/peptides_oligos/correlation/index.md)
- [Production route](https://www.materialinsights.org/chemicals/peptides_oligos/routes/index.md)
- [Feedstocks](https://www.materialinsights.org/chemicals/peptides_oligos/feedstocks/index.md)
- [Cycles](https://www.materialinsights.org/chemicals/peptides_oligos/cycles/index.md)
- [Trading](https://www.materialinsights.org/chemicals/peptides_oligos/trading/index.md)
- [Movement](https://www.materialinsights.org/chemicals/peptides_oligos/movement/index.md)
- [Regulation](https://www.materialinsights.org/chemicals/peptides_oligos/regulation/index.md)
- [Characteristics](https://www.materialinsights.org/chemicals/peptides_oligos/characteristics/index.md)
- [Emissions](https://www.materialinsights.org/chemicals/peptides_oligos/emissions/index.md)
- [Relationships](https://www.materialinsights.org/chemicals/peptides_oligos/links/index.md)